Cardiac events after using clarithromycin for anti-Helicobacter pylori therapy in patients with coronary artery disease
Open Access
- 10 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35922
Abstract
Clarithromycin is an antibiotic commonly used to treat Helicobacter pylori infections. The US Food and Drug Administration (FDA) advises caution before prescribing clarithromycin to patients with cardiac diseases. This study aimed to evaluate cardiac events after anti-H pylori treatment in patients with coronary artery disease. A retrospective 5-year study was conducted on outpatients who received anti-H pylori therapy. Among the 7855 patients receiving therapy, 228 patients (2.9%) underwent angiography with coronary artery disease before therapy, and 193 patients received clarithromycin. Clarithromycin users seemed not to be at risk for cardiac events as compared with non-clarithromycin users at 3 months (4.7% vs 2.9%, P = .63) and 1 year (10.9% vs 5.7%, P = .35). Neither life-threatening dysrhythmia nor cardiac death was noted. The risk factors for cardiac events within 3 months after therapy were smoker (OR:5.38, 95% CI:1.39–20.78), and events within 1 year were smoker (OR:3.8, 95% CI:1.41–10.22), and diabetes mellitus (OR:5.68, 95% CI:1.9–16.98). Among patients with coronary artery disease who received anti-H pylori therapy, short-term cardiac events did not increase in clarithromycin users but should be considered in diabetic and smoking patients.Keywords
This publication has 15 references indexed in Scilit:
- Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self‐controlled study designsBritish Journal of Clinical Pharmacology, 2016
- The Role of Macrolide Antibiotics in Increasing Cardiovascular RiskJACC, 2015
- Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trialInternational Journal of Cardiology, 2015
- Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studiesBMJ, 2013
- Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?Cardiology, 2011
- Clarithromycin Use and Risk of Death in Patients with Ischemic Heart DiseaseCardiology, 2010
- Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart DiseaseJournal of Cardiovascular Pharmacology, 2010
- One-Year Cardiovascular Event Rates in Outpatients With AtherothrombosisJAMA, 2007
- Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetesHeart, 2006
- Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialBMJ, 2005